90434-01-8

Basic information

• Product Name: 3-iodo-N-methylbenzamide
• Synonyms: 3-iodo-N-methylbenzamide
• CAS NO: 90434-01-8
• Molecular Formula: C₈H₈INO
• Molecular Weight: 261.06
• Mol File: 90434-01-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-iodo-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-iodo-N-methylbenzamide(90434-01-8)
• EPA Substance Registry System: 3-iodo-N-methylbenzamide(90434-01-8)

Safety Data

• Hazardous Substances Data: 90434-01-8(Hazardous Substances Data)

Usage

Description

3-Iodo-N-methylbenzamide is a chemical compound with the molecular formula C8H8INO. It is a derivative of benzamide, containing a methyl group and an iodine atom attached to the benzene ring. 3-iodo-N-methylbenzamide is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules. Due to its structural similarity to other biologically active compounds, it may also have potential applications in medicinal chemistry and drug development. As with any chemical compound, proper handling and disposal procedures should be followed to ensure safety and environmental protection.

Uses

Used in Organic Synthesis:
3-Iodo-N-methylbenzamide is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure, featuring a methyl group and an iodine atom attached to the benzene ring, allows for the development of a wide range of compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-Iodo-N-methylbenzamide is utilized as a key component in the synthesis of new drugs and drug candidates. Its structural similarity to other biologically active compounds makes it a valuable asset in the discovery and development of novel therapeutic agents.
Used in Medicinal Chemistry:
3-Iodo-N-methylbenzamide may have potential applications in medicinal chemistry, where it can be used to explore the structure-activity relationships of various compounds. This can lead to the optimization of drug candidates and the development of more effective treatments for a variety of diseases and conditions.
Used in Drug Development:
Due to its potential as a building block for the synthesis of biologically active molecules, 3-Iodo-N-methylbenzamide can be employed in drug development to create new pharmaceuticals. Its unique properties and structural features make it a promising candidate for the development of innovative treatments and therapies.

Upstream product

• 74-89-5 methylamine 
• 618-51-9 3-Iodobenzoic acid 
• 1711-10-0 3-iodobenzoyl chloride 
• 1197171-76-8 N-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide 
• 593-51-1 methylamine hydrochloride 
• 618-91-7 methyl 3-iodo-benzoate 

Downstream Products

• 694528-54-6 trans-iodo(N-methylbenzamide-C⁽³⁾)bis(triphenylphosphine)platinum(II) 
• 1033438-99-1 N-methyl-3-[(trimethylsilyl)ethynyl]benzamide 

Relevant articles and documents

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound as well as preparation and application thereof

The invention belongs to the technical field of medicines. The invention relates to the field of pharmaceutical chemistry, in particular to a 4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound and pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in preparation of an MNK inhibitor and drugs for treating and/or preventing various cancers and/or metabolic diseases. The present invention relates to compounds represented by formulas I, II, III or IV, and pharmaceutically acceptable salts, hydrates, solvates and metabolites thereof, wherein the variables are described in the claims and the description.

Chemoselective Synthesis of Aryl Ketones from Amides and Grignard Reagents via C(O)-N Bond Cleavage under Catalyst-Free Conditions

Conversion of a wide range of N-Boc amides to aryl ketones was achieved with Grignard reagents via chemoselective C(O)-N bond cleavage. The reactions proceeded under catalyst-free conditions with different aryl, alkyl, and alkynyl Grignard reagents. α-Ketoamide was successfully converted to aryl diketones, while α,β-unsaturated amide underwent 1,4-addition followed by C(O)-N bond cleavage to provide diaryl propiophenones. N-Boc amides displayed higher reactivity than Weinreb amides with Grignard reagents. A broad substrate scope, excellent yields, and quick conversion are important features of this methodology.